Phase 3 LUCIDITY topline data release set for tomorrow drives AMLX
in after-hours surge
- Amylyx announced after close on Aug 17 that pivotal Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia (PBH) will be released Aug 18 with 8am ET conference call
- Previously guided as late August or early September after final patient visit completion; pinning exact date created immediate catalyst
- Mizuho simultaneously raised PT to $30 from $24 (Outperform rating), citing higher launch pricing assumptions for avexitide ahead of data
- Avexitide holds FDA Breakthrough Therapy Designation; ~160k US PBH patients represent substantial market opportunity
- Stock surged ~14.5-15.5% to near $24.50 in after-hours trading on optimism for positive binary readout
- Q2 2026 results and cash runway into 2028 (reported Aug 6) provided foundation but Aug 17 news was the specific trigger
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.